Gilead Sciences Financial Health
Financial Health criteria checks 4/6
Gilead Sciences has a total shareholder equity of $20.9B and total debt of $25.2B, which brings its debt-to-equity ratio to 120.5%. Its total assets and total liabilities are $61.9B and $40.9B respectively. Gilead Sciences's EBIT is $10.2B making its interest coverage ratio 11. It has cash and short-term investments of $6.5B.
Key information
120.5%
Debt to equity ratio
US$25.24b
Debt
| Interest coverage ratio | 11x |
| Cash | US$6.52b |
| Equity | US$20.94b |
| Total liabilities | US$40.94b |
| Total assets | US$61.88b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GIS's short term assets ($13.5B) exceed its short term liabilities ($10.5B).
Long Term Liabilities: GIS's short term assets ($13.5B) do not cover its long term liabilities ($30.4B).
Debt to Equity History and Analysis
Debt Level: GIS's net debt to equity ratio (89.4%) is considered high.
Reducing Debt: GIS's debt to equity ratio has reduced from 140.7% to 120.5% over the past 5 years.
Debt Coverage: GIS's debt is well covered by operating cash flow (35.6%).
Interest Coverage: GIS's interest payments on its debt are well covered by EBIT (11x coverage).